Yayınlar & Eserler

Yayın Ağı
Makaleler 84
Tümü (84)
SCI-E, SSCI, AHCI (74)
SCI-E, SSCI, AHCI, ESCI (79)
ESCI (4)
Scopus (81)
TRDizin (12)

1. Real-world associations of pathological complete response and survival with neoadjuvant pembrolizumab in early TNBC: a Turkish Oncology Group study

Muğlu H., SÜNGER E., Özkan O., ŞAHİN T. K., Köylü B., Helvacı K., et al.
Scientific Reports , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus) Creative Commons License

2. Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer

Sahin T. K., Orhan C., Ozercan I. H., Muglu H., Er B., Akyildiz A., et al.
Experimental Hematology and Oncology , cilt.15, sa.1, 2026 (SCI-Expanded, Scopus) Creative Commons License

3. The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study

Oruç A., Deliktaş Onur İ., Uyar G. C., Şahin T. K., Tünbekici S., ARSLAN KAPUCİ A., et al.
Scientific Reports , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus) Creative Commons License

4. Radiological Response to Capecitabine and Temozolomide in an Elderly Patient with Metastatic Leiomyosarcoma: A Case Report

YALÇIN Ş., Kilinc C., ŞAHİN T. K., DİZDAR Ö.
Journal of Clinical Medicine , cilt.15, sa.17, 2026 (SCI-Expanded, Scopus)

5. Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

Tunbekici S., Bal H., Kınıkoglu O., Arvas H., Muglu H., BİLİCİ A., et al.
Clinical and Translational Oncology , cilt.28, sa.8, ss.3160-3169, 2026 (SCI-Expanded, Scopus)

6. Safety evaluation of TOPAZ-1 and KEYNOTE-966 regimens in metastatic biliary tract cancer: a systematic review and meta-analysis

Vitale E., Maistrello L., Ciccimarra F., GÜVEN D. C., ŞAHİN T. K., Monteiro F. S. M., et al.
Clinical and Experimental Metastasis , cilt.43, sa.4, 2026 (SCI-Expanded, Scopus)

7. Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory Biomarkers

Şahin G., Dişli A. K., ŞİRVAN F., Mıdık M. M., Boyraz N. E., Belen O., et al.
Medicina (Lithuania) , cilt.62, sa.7, 2026 (SCI-Expanded, Scopus)

8. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

Köylü B., Celayir Ö. M., Muğlu H., Can O., Şen F., Öven B. B., et al.
Cancers , cilt.18, sa.12, 2026 (SCI-Expanded, Scopus)

9. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Seyyar M., Kalem A., SALİ M., Karabuğa B., ŞAHİN T. K., Dişli A. K., et al.
Current Oncology , cilt.33, sa.6, 2026 (SCI-Expanded, Scopus)

10. Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group

Tunbekici S., Sahin G., Ön S., Oruc A., Eryılmaz M. K., SAKİN A., et al.
International Journal of Cancer , cilt.158, sa.7, ss.1881-1890, 2026 (SCI-Expanded, Scopus)

11. Serum Vitamin D Levels as a Prognostic Biomarker in Patients Receiving Immune Checkpoint Inhibitors

Şahi̇n T. K., BAŞ O., KAVGACI G., Güdük N., ŞİRVAN F., AKIN S., et al.
Journal of Oncological Science , cilt.12, sa.1, ss.1-8, 2026 (Scopus, TRDizin) Creative Commons License

12. Survival Outcomes and Prognostic Factors in Head and Neck Adenoid Cystic Carcinoma Following Curative Surgery

Bölek H., Kayaalp M., Şahi̇n T. K., DOĞAN O. T., YÜKSEL S., DURU BİRGİ S., et al.
Journal of Oncological Science , cilt.12, sa.1, ss.51-58, 2026 (Scopus, TRDizin) Creative Commons License

13. Prognostic Value of Baseline Sarcopenia and Adipose Tissue Indices in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors: A Retrospective Cohort Study

Karahan L., Akyildiz A., Sahin T. K., Batu M. A., ERŞAN Y. Ç., ONUR M. R., et al.
Journal of Clinical Medicine , cilt.15, sa.4, 2026 (SCI-Expanded, Scopus)

14. Cell therapy in sarcoma: Current landscape and future directions

Sahin T. K., Germetaki T., GÜVEN D. C., AKIN S., DİZDAR Ö., Thistlethwaite F., et al.
Journal for ImmunoTherapy of Cancer , cilt.14, sa.1, 2026 (SCI-Expanded, Scopus)

15. Expression and prognostic value of cytotoxic T-lymphocyte-associated 4 protein in classic Hodgkin lymphoma

Sahin T. K., Gungor H. N., Gezmis E., Sahin E. A., BARIŞTA İ., AYHAN E. A., et al.
Expert Review of Hematology , cilt.19, sa.8, ss.967-973, 2026 (SCI-Expanded, Scopus)

16. Artificial intelligence in cancer screening: a narrative review of current evidence and future directions

Yazarkan Y., Sonmez G., Sahin T. K., Rizzo A., GÜVEN D. C.
Expert Review of Molecular Diagnostics , cilt.26, sa.2, ss.149-172, 2026 (SCI-Expanded, Scopus)

17. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

Sahin T. K., Kemik F., Muglu H., Acikgöz Yildiz B., Biter S., Tunbekici S., et al.
Therapeutic Advances in Medical Oncology , cilt.18, 2026 (SCI-Expanded, Scopus)

18. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

Güren A. K., DEMİRCAN N. C., GÜMÜŞAY Ö., Şimşek E. T., Kemik F., KARAOĞLU Ç., et al.
Immunotherapy , cilt.18, sa.4, ss.317-326, 2026 (SCI-Expanded, Scopus)

19. Harnessing the power of artificial intelligence for clinical trials in cancer

Sonmez G., Yazarkan Y., Sahin T. K., GÜVEN D. C.
Expert Review of Anticancer Therapy , cilt.26, sa.6, ss.735-749, 2026 (SCI-Expanded, Scopus)

20. Epidemiology and Clinical Profiles of Bacteroides fragilis Bacteremia in a Tertiary Care Setting: A 5-Year Review

SÖNMEZER M. Ç., ERUL E., Aka Türkmen N., ŞAHİN T. K., Demir Cuha M., HAZIROLAN G., et al.
Canadian Journal of Infectious Diseases and Medical Microbiology , cilt.2026, sa.1, 2026 (SCI-Expanded, Scopus)

21. Elacestrant in metastatic breast cancer: current advancements and future perspectives

Sahin T. K., Makasheva B., GÜVEN D. C., AKSOY S., Di Lauro V., Rizzo A.
Expert Review of Anticancer Therapy , cilt.26, sa.6, ss.697-706, 2026 (SCI-Expanded, Scopus)

22. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

Majidova N., YASLIKAYA Ş., Mildanoglu M. M., COŞKUN A., ERCAN UZUNDAL D., ŞAHİN T. K., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.36, sa.5, ss.293-301, 2025 (SCI-Expanded, Scopus, TRDizin)

23. Fear of Cancer Recurrence and Associated Factors in Lymphoma Survivors and Their Family Caregivers: A Cross-Sectional Study

ŞAHİN T. K., Sahin E. A., Gungor H. N., GÜVEN D. C., BARIŞTA İ., AKIN S.
CANCER MEDICINE , cilt.14, sa.7, 2025 (SCI-Expanded, Scopus)

24. Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer

Sahin T. K., Rizzo A., GÜVEN D. C., AKSOY S.
CANCER TREATMENT REVIEWS , cilt.135, 2025 (SCI-Expanded, Scopus)

25. The role of the microbiome in head and neck squamous cell cancers

ŞAHİN T. K., SÖNMEZER M. Ç.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY , cilt.282, sa.2, ss.623-637, 2025 (SCI-Expanded, Scopus)

26. The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitors

ŞAHİN T. K., GÜVEN D. C., Durukan M., KAVGACI G., KAYGUSUZ Y., ARIK Z., et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS , cilt.25, sa.4, ss.129-137, 2025 (SCI-Expanded, Scopus)

27. Ribociclib-induced autoimmune-like hepatitis: a case report

KAVGACI G., ŞAHİN T. K., SÖKMENSÜER C., BALABAN H. Y., AKSOY S.
JOURNAL OF CHEMOTHERAPY , cilt.37, sa.8, ss.741-746, 2025 (SCI-Expanded, Scopus)

28. The perspectives and knowledge of patients with cancer on mpox and mpox vaccination: a cross-sectional study

ŞAHİN T. K., KAYGUSUZ Y., Icli M. C., AKSOY S., GÜVEN D. C.
CURRENT MEDICAL RESEARCH AND OPINION , cilt.41, sa.1, ss.83-91, 2025 (SCI-Expanded, Scopus)

29. The association between HALP score and survival in patients treated with immune checkpoint inhibitors

ŞAHİN T. K., GÜVEN D. C., Durukan M., BAŞ O., KAYGUSUZ Y., ARIK Z., et al.
EXPERT REVIEW OF ANTICANCER THERAPY , cilt.25, sa.1, ss.81-89, 2025 (SCI-Expanded, Scopus)

30. Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors

ŞAHİN T. K., AKSOY S., GÜVEN D. C.
EXPERT REVIEW OF ANTICANCER THERAPY , cilt.25, sa.5, ss.471-484, 2025 (SCI-Expanded, Scopus)

31. Modified cachexia index and survival in metastatic breast cancer patients treated with CDK 4-6 inhibitors

BAŞ O., Tokatli M., Savkliyildiz M., Yazarkan Y., Guduk N., Kilinc C., et al.
EXPERT REVIEW OF ANTICANCER THERAPY , cilt.25, sa.4, ss.405-409, 2025 (SCI-Expanded, Scopus)

32. Prognostic Value of Neutrophil-to-Eosinophil Ratio (NER) in Cancer: A Systematic Review and Meta-Analysis

ŞAHİN T. K., Ayasun R., Rizzo A., Guven D. C.
CANCERS , cilt.16, sa.21, 2024 (SCI-Expanded, Scopus)

33. Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: A systematic review and meta-analysis

Sahin T. K., Guven D. C.
CLINICAL NUTRITION ESPEN , cilt.63, ss.829-836, 2024 (ESCI, Scopus)

34. Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine

ŞAHİN T. K., AKYILDIZ A., DOĞAN O. T., KAVGACI G., GÜVEN D. C., AKSOY S.
PHARMACEUTICALS , cilt.17, sa.7, 2024 (SCI-Expanded, Scopus) Creative Commons License

35. Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy

Sahin T. K., ÖZBAY Y., ALTUNBULAK A. Y., ALTUNBULAK H. İ., ONUR M. R., Ceylan F., et al.
International Journal of Clinical Oncology , cilt.29, sa.6, ss.822-831, 2024 (SCI-Expanded, Scopus)

36. Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis

Sahin T. K., Rizzo A., AKSOY S., Guven D. C.
CANCERS , cilt.16, sa.10, 2024 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

37. The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysis

Guven D. C., Sahin T. K.
Breast Cancer Research and Treatment , cilt.204, sa.3, ss.443-452, 2024 (SCI-Expanded, Scopus)

38. Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer

KAVGACI G., ŞAHİN T. K., Muderrisoglu T., Ileri S., GÜVEN D. C., AKSOY S.
EXPERT REVIEW OF ANTICANCER THERAPY , cilt.24, sa.12, ss.1319-1326, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

39. Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis

GÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., AKSOY S.
Laryngoscope , cilt.134, sa.1, ss.7-17, 2024 (SCI-Expanded, Scopus)

40. Diagnostic performance and longitudinal analysis of fungal biomarkers in COVID-19 associated pulmonary aspergillosis

ER B., ER A. G., GÜLMEZ KIVANÇ D., ŞAHİN T. K., METAN G., SARIBAŞ Z., et al.
Heliyon , cilt.9, sa.11, 2023 (SCI-Expanded, Scopus)

41. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study

GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.149, sa.7, ss.3599-3606, 2023 (SCI-Expanded, Scopus)

42. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.
Anti-Cancer Drugs , cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus)

43. Modulation of inflammation by phytochemicals to enhance efficacy and reduce toxicity of cancer chemotherapy

ŞAHİN T. K., Bilir B., Kucuk O.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION , cilt.63, sa.15, ss.2494-2508, 2023 (SCI-Expanded, Scopus)

44. Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data

Sütcüoğlu O., Doğan A., Yilmaz F., Şahin A. B., ŞAHİN T. K., Esen S. A., et al.
Pancreas , cilt.52, sa.4, 2023 (SCI-Expanded, Scopus)

45. Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer

Ceylan F., Guven D. C., Taban H., Aktepe O., ŞAHİN T. K., Kilickap S., et al.
Clinics and Research in Hepatology and Gastroenterology , cilt.47, sa.3, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

46. Knowledge and Attitudes of Turkish Physicians towards Human Monkeypox Disease and Related Vaccination: A Cross-Sectional Study

ŞAHİN T. K., ERUL E., AKSUN M. S., SÖNMEZER M. Ç., ÜNAL S., AKOVA M.
Vaccines , cilt.11, sa.1, 2023 (SCI-Expanded, Scopus) Creative Commons License

47. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

GÜVEN D. C., ŞAHİN T. K., ERUL E., Rizzo A., Ricci A. D., AKSOY S., et al.
Frontiers in Molecular Biosciences , cilt.9, 2022 (SCI-Expanded, Scopus) Creative Commons License

48. The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges

GÜVEN D. C., ŞAHİN T. K., Rizzo A., Ricci A. D., AKSOY S., ŞAHİN K.
APPLIED SCIENCES-BASEL , cilt.12, sa.20, 2022 (SCI-Expanded, Scopus) Creative Commons License

49. Independent predictors of in-hospital mortality and the need for intensive care in hospitalized non-critical COVID-19 patients: a prospective cohort study

ÇALIK BAŞARAN N., ÖZDEDE M., UYAROĞLU O. A., ŞAHİN T. K., ÖZCAN B., ORAL H., et al.
INTERNAL AND EMERGENCY MEDICINE , cilt.17, sa.5, ss.1413-1424, 2022 (SCI-Expanded, Scopus) Creative Commons License

50. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al.
JOURNAL OF CLINICAL MEDICINE , cilt.11, sa.15, 2022 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

51. A screening study for COVID-19-associated pulmonary aspergillosis in critically ill patients during the third wave of the pandemic

ER B., ER A. G., GÜLMEZ KIVANÇ D., ŞAHİN T. K., HALAÇLI B., DURHAN G., et al.
MYCOSES , cilt.65, ss.724-732, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

52. Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey

SÖNMEZER M. Ç., TELLİ DİZMAN G., Erul E., ŞAHİN T. K., SARICAOĞLU T., Alp A., et al.
VACCINES , cilt.10, sa.7, 2022 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

53. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy

GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.4, ss.785-793, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

54. The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis

GÜVEN D. C., ŞAHİN T. K., Erul E., KILIÇKAP S., Gambichler T., AKSOY S.
CANCERS , cilt.14, sa.11, 2022 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

55. The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials

GÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., Erul E., AKSOY S.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , cilt.174, 2022 (SCI-Expanded, Scopus)

56. Seroprevalence of SARS-CoV-2 Antibodies and Associated Factors in Healthcare Workers before the Era of Vaccination at a Tertiary Care Hospital in Turkey

SÖNMEZER M. Ç., Erul E., ŞAHİN T. K., Rudvan Al I., Cosgun Y., Korukluoglu G., et al.
VACCINES , cilt.10, sa.2, 2022 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

57. Knowledge, Attitudes, and Perception towards COVID-19 Vaccination among the Adult Population: A Cross-Sectional Study in Turkey

SÖNMEZER M. Ç., ŞAHİN T. K., Erul E., Ceylan F. S., Hamurcu M. Y., Morova N., et al.
VACCINES , cilt.10, sa.2, 2022 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

58. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study

GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

59. Hyperlipidemia in Post-COVID patients; a unique observational follow-up study on lipid levels in post-COVID patients

UYAROĞLU O. A., ÖZDEDE M., ÇALIK BAŞARAN N., KÖYLÜ B., ŞAHİN T. K., ÖZIŞIK L., et al.
JOURNAL OF HEALTH SCIENCES AND MEDICINE , cilt.5, sa.1, ss.220-226, 2022 (TRDizin)

60. Evaluation of Corrected QT Intervals of 74 COVID19 Patients Treated with Hydroxychloroquine in Combination with or without Azithromycin and/or Favipiravir

UYAROĞLU O. A., ŞENER Y. Z., ÖZDEDE M., ÇALIK BAŞARAN N., ÖZIŞIK L., ŞAHİN T. K., et al.
European Journal of Therapeutics , cilt.27, sa.4, ss.311-317, 2021 (ESCI, TRDizin) Sürdürülebilir Kalkınma

61. Correlation Between THSD7A Expression and Tumor Characteristics of Azoxymethane-Induced Colon Cancer Model in Rats

AKTEPE O. H., ŞAHİN T. K., GÜNER G., GÜVEN D. C., YETER H. H., KURTULAN O., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.32, sa.12, ss.1049-1056, 2021 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

62. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., AKTEPE O. H., DİZDAR Ö., YALÇIN Ş.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , cilt.168, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

63. The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy

AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEN B., Yeter H. H., et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL , cilt.73, sa.10, ss.1957-1963, 2021 (SCI-Expanded, Scopus)

64. Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review

GÜVEN D. C., ŞAHİN T. K., KILIÇKAP S., Uckun F. M.
FRONTIERS IN ONCOLOGY , cilt.11, 2021 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

65. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

66. Clinical Outcomes and Independent Risk Factors for 90-Day Mortality in Critically Ill Patients with Respiratory Failure Infected with SARS-CoV-2: A Multicenter Study in Turkish Intensive Care Units

GÜNDOĞAN K., AKBUDAK İ. H., Hanci P., HALAÇLI B., TEMEL Ş., Gullu Z., et al.
BALKAN MEDICAL JOURNAL , cilt.38, sa.5, ss.296-305, 2021 (SCI-Expanded, Scopus, TRDizin) Creative Commons License Sürdürülebilir Kalkınma

67. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.
SUPPORTIVE CARE IN CANCER , cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

68. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors

GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.
BIOMARKERS IN MEDICINE , cilt.15, sa.13, ss.1123-1130, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

69. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.36, 2021 (SCI-Expanded, Scopus)

70. Artificial intelligence method to predict overall survival of hepatocellular carcinoma

ŞİMŞEK C., GÜVEN D. C., Sahin T. K., TEKİN İ. E., Sahan O., BALABAN H. Y., et al.
Hepatology Forum , cilt.2, sa.2, ss.64-68, 2021 (Scopus)

71. Artificial Intelligence to Predict Esophageal Varices in Patients with Cirrhosis

TEKİN İ. E., ŞİMŞEK C., BALABAN H. Y., ŞAHİN T. K.
Acıbadem Üniversitesi Sağlık Bilimleri Dergisi , cilt.12, ss.625-629, 2021 (TRDizin)

72. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., et al.
SUPPORTIVE CARE IN CANCER , cilt.29, sa.4, ss.2029-2035, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

73. Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma

AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., et al.
TURKISH JOURNAL OF UROLOGY , cilt.47, sa.2, ss.113-119, 2021 (ESCI, Scopus, TRDizin)

74. Thyroid gland metastasis mimicking thyroid carcinoma in a lung cancer patient and dramatic response to crizotinib: A case report

Erul E., GÜVEN D. C., ŞAHİN T. K., Gullu İ. H.
TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX , cilt.69, sa.1, ss.98-101, 2021 (ESCI, Scopus, TRDizin) Creative Commons License Sürdürülebilir Kalkınma

75. Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients

İNKAYA A. Ç., KARA E., ÇALIK BAŞARAN N., ŞAHİN T. K., UYAROĞLU O. A., UZUN Ö., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.51, sa.5, ss.2786-2788, 2021 (SCI-Expanded, Scopus, TRDizin) Creative Commons License Sürdürülebilir Kalkınma

76. Artificial intelligence to predict overall survivals of patients with cirrhosis and outcomes of variceal bleeding

BALABAN H. Y., TEKİN İ. E., ŞAHİN T. K., SİVRİ B.
Hepatology forum , 2021 (Scopus)

77. The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters

GÜVEN D. C., ŞAHİN T. K., AKSOY S.
BREAST JOURNAL , cilt.26, sa.12, ss.2435-2436, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

78. Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives

C Guven D., ŞAHİN T. K., DİZDAR Ö., KILIÇKAP S.
BIOMARKERS IN MEDICINE , cilt.14, ss.1383-1392, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

79. All Positives May Not Be the Same in Pancreatic Cancer Lessons Learned From the Past

Ceylan F., GÜVEN D. C., ŞAHİN T. K., ÖZBEK D. A., DİZDAR Ö.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.43, sa.9, ss.676, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

80. Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19

GÜVEN D. C., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., AKSOY S., KILIÇKAP S.
FRONTIERS IN ONCOLOGY , cilt.10, 2020 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

81. Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61

ŞAHİN T. K., AKTEPE O. H., Uckun F. M., YALÇIN Ş.
ANTI-CANCER DRUGS , cilt.31, sa.6, ss.609-616, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

82. Spontaneous subepithelial hemorrhage of renal pelvis and ureter (Antopol-Goldman lesion) in hemophilia A patient with inhibitor Case report and review of the literature

ŞAHİN T. K., ALADAĞ KARAKULAK E., Setterzade E., SAİN GÜVEN G., HAZNEDAROĞLU İ. C., AKSU S.
MEDICINE , cilt.99, sa.26, 2020 (SCI-Expanded, Scopus)

83. Prevention of DMBA-induced mammary gland tumors in mice by a dual-function inhibitor of JAK3 and EGF receptor tyrosine kinases

ŞAHİN K., YABAŞ M., ORHAN C., TUZCU M., ŞAHİN T. K., ÖZERCAN İ. H., et al.
EXPERT OPINION ON THERAPEUTIC TARGETS , cilt.24, sa.4, ss.379-387, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

84. Chemopreventive efficacy of stampidine in a murine breast cancer model

ŞAHİN K., ORHAN C., ÖZERCAN İ. H., TUZCU M., ELİBOL B., ŞAHİN T. K., et al.
EXPERT OPINION ON THERAPEUTIC TARGETS , cilt.24, sa.2, ss.155-162, 2020 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 4

1. SURVEILLANCE FOR INVASIVE PULMONARY ASPERGILLOSIS IN CRITICALLY ILL PATIENTS WITH COVID-19

ER B., ER A. G., GÜLMEZ KIVANÇ D., ŞAHİN T. K., HALAÇLI B., DURHAN G., et al.
18. ULUSAL DAHİLİ VE CERRAHİ BİLİMLER YOĞUN BAKIM E-KONGRESİ VE 10. AVRASYA YOĞUN BAKIM E-TOPLANTISI, Ankara, Türkiye, 6 - 09 Aralık 2021, cilt.12, (Özet Bildiri) Sürdürülebilir Kalkınma

2. ANKARA’DA BAZI AKARYAKIT İSTASYONLARINDA ÇALIŞANLARIN İSTASYONDA OLASI BİR YANGIN/PATLAMA ÖNCESİ/SIRASI/SONRASINDA YAPILACAKLAR KONUSUNDA BAZI BİLGİ VE GÖRÜŞLERİ

ERCAN T. M. F., Çakır İ. Y., ŞAHİN T. K., Ayhan B., Bulut R., GÜLBAHÇE F. G., et al.
2.Uluslararası - 20.Ulusal Halk Sağlığı Kongresi, 13 - 17 Kasım 2018, (Özet Bildiri)

3. THE EFFECTS OF BMI ON RESPIRATORY AND HEMODYNAMIC PARAMETERS IN LAPAROSCOPIC BARIATRIC SURGERY: AN OBSERVATIONAL STUDY

Ayyildiz A., PAMUK A. G., ÜZÜMCÜGİL F., AKÇA B., Yilbas A. A., ŞAHİN T. K., et al.
20th World Congress of the International-Federation-for-the-Surgery-of-Obesity-and-Metabolic-Disorders (IFSO), Vienna, Avusturya, 26 - 29 Ağustos 2015, cilt.25, (Özet Bildiri)

4. Mineralogical and geochemical characteristics of the borate bearing Kirka volcanosedimentary lacustrine basin, Gocenoluk Area, Eskisehir, Western Anatolia, Turkey: Preliminary results

ŞAHİN T. K., TEMEL A., Sylvester P.
19th Annual VM Goldschmidt Conference, Davos, İsviçre, 21 Haziran 2009, cilt.73, (Özet Bildiri)
Metrikler

Yayın

88

Yayın (WoS)

81

Yayın (Scopus)

81

Atıf (WoS)

223

H-İndeks (WoS)

8

Atıf (Scopus)

988

H-İndeks (Scopus)

14

Atıf (Scholar)

2

H-İndeks (Scholar)

1

Atıf (TrDizin)

1

H-İndeks (TrDizin)

1

Atıf (Sobiad)

1

H-İndeks (Sobiad)

1

Atıf (Diğer Toplam)

1

Açık Erişim

24
BM Sürdürülebilir Kalkınma Amaçları
SDG 3: AMAÇ 3: SAĞLIKLI BİREYLER
SDG 16: AMAÇ 16: BARIŞ VE ADALET
SDG 17: AMAÇ 17: AMAÇLAR İÇİN ORTAKLIKLAR